October 13, 2021 7:45am

News: Crispr Therapeutics (CRSP) is diving -5% in premarket trade despite generally positive P1 test results of a gene-edited cancer drug. CRSP planning to begin a pivotal study of its gene-edited cancer drug, CTX 110. Of the 26 lymphoma patients, 38% had no detectable cancer following the treatment. There were no major side effects.

Pre-open indications: 5 SELLs and 1 Pump (or No Promote)

What I provide is an intelligence daily. RMi outlines the prelude to the daily dose of facts and objectivity! My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.

Dow futures are UP +0.13% (+46 points), S&P futures are UP +0.20% (+9 point) and NASDAQ futures are UP +0.46% (+67 point)

 

U.S. stock futures were slightly higher on Wednesday,

European markets were soft,

Asia-Pacific markets were mixed as investors reacted to the release of Chinese trade data for September. The figures showed exports beat expectations but import growth disappointed.

 

Henry’omics:

The S&P 500, Dow and Nasdaq each posted a third (3rd) consecutive day of declines.

 

Economic data Docket: The consumer price index for September; economists expect prices for an array of consumer goods to jump 0.3% in September from the month prior and 5.3% year over year.

  • Economists expect to see a rise of 0.3%, or a 5.3% annualized rate, when the consumer price index is released at 8:30 a.m. E.T. Excluding energy and food, CPI is forecast to be up 0.3% month-over-month or 4% annualized.

 

If you didn’t remember what happen at Tuesday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:

  • Tuesday’s evening’s recap: “love the upside but, the highs won’t last as Q3 results are being prepared for disposition. I hope you’re stockpiling some “powder i.e., cash” in your portfolio.” … https://www.regmedinvestors.com/articles/12135

Q4: October, 4 positive and 4 negative closes

Q3/21:

  • September, 1 holiday, 10 positive and 10 negative close
  • August - 12 positive and 10 negative close
  • July: 6 positives, 1 holiday and 15 negative closes

 

Companies in my headlights – It’s your decision; I provide an idea and context:

SELL with a Pump or no promote:

Biostage (BSTG) closed down -$0.20 to $3.01 with 614 shares traded after Monday’s flat after Friday’s $0.00 (flat) with 32 shares traded following Thursday’s +$0.19 to $3.21 with 612 shares traded after Wednesday’s -$0.02 to $3.02 after last Tuesday’s -$0.59.

  • For a company with NO clinical trial, an a one (1) and a half year approved IND, four (4) employees and NO CRO <clinical research organization> initiation. What’s there to invest in – the “Sword of Damocles” hanging over its recent insurance company rejection of legal expense/costs of a terminal death suit against the company?

 

Maintaining SELL:
CRISPR Therapeutics (CRSP) closed up +$1.94 to $102.59 after Monday’s +$2.02 to $100.65, Friday’s -$4.36 to $98.63, Thursday’s +$1.00 to $102.99 and last Wednesday’s -$0.50 to $101.99 with a negative -$8.59 or -8.37% pre-market indication on news of CRISP’s stock follows Allogene's (ALLO) path and Dives on Gene-Editing test. The results come at a pivotal time for the field. Last week, ALLO’s stock collapsed after the FDA placed its CAR-T study on hold, citing safety issues. ALLO uses several different technologies to create its "off-the-shelf" CAR-T. It uses a gene-editing method called TALENS and a non-harmful lentivirus to deliver the drug. Crispr's CTX110 relies on CRISPR technology for both the editing and drug delivery. Still, CRSP stock could fall -5.08% or -$5.21 <again>.

 

SELL:

Ionis Pharmaceuticals (IONS) closed down -$0.40 to $34.01 with a negative -$0.51 or -1.50% aftermarket indication.

 

SELL into Strength:

BioLife Solutions (BLFS) closed up +$0.59 to $38.45 with a positive +$0.35 or +0.91% aftermarket indication.

Fate Therapeutics (FATE) closed up +$2.52 to $59.07 with a positive +$1.33 or +2.25% aftermarket indication.

Homology Medicine (FIXX) closed up +$0.08 to $6.57 with a positive =$0.37 or +5.63% aftermarket indication.

 

ReNeuron (RENE.L) closed up $20.70 to $115.50 after Friday’s +$2.30 at $94.80 with a negative -$0.55 or -0.47% pre-market indication.

 

The BOTTOM LINE:  I am STILL NOT taking any action until the market’s direction is confirmed and as goes the stem cell and gene therapy sector.

Theme is too much uncertainty, what’s more likely to me is skepticism …

Sector stocks have traded choppily over the past several weeks as investors contemplated the implications of ongoing price increases (i.e., inflation) against a backdrop of decelerating economic growth.

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.